LaDuane Clifton
Equibles does not estimate personal net worth.
About LaDuane Clifton
Earlier roles on record: CFO at Zevra Therapeutics, Inc. (ZVRA) until December 31, 2025. Zevra Therapeutics, Inc. reported in an 8-K filed November 20, 2025 that LaDuane Clifton resigned as Chief Financial Officer and Treasurer and principal financial officer, effective December 31, 2025. The proxy statement of Zevra Therapeutics, Inc. reports total compensation of $3,821,924 for LaDuane Clifton in fiscal 2025, including a base salary of $477,307. Disclosed compensation is on record for 8 fiscal years. LaDuane Clifton has spoken on 23 earnings calls across 1 company, most recently for Zevra Therapeutics, Inc. on November 5, 2025. The companies whose calls LaDuane Clifton spoke on are classified in the Healthcare sector.
“On November 20, 2025, R. LaDuane Clifton, the Chief Financial Officer and Treasurer and principal financial officer of Zevra Therapeutics, Inc. (the “Company”) notified the Company of his decision to resign from his position, effective December 31, 2025 (the “Separation Date”), in order to pursue other professional opportunities.”
LaDuane Clifton on recent calls
“In addition to the financial details included in today's call, we encourage you to refer to Zevra's quarterly report on Form 10-Q for more detailed information, which we intend to file later today.”
“In addition to the financial details included in today's call, we encourage you to refer to Zebra's quarterly report on Form 10-Q for more detailed information, which we intend to file later today.”
“In addition to the financial details included in today's call, we encourage you to refer to Zebra's quarterly report on Form 10-Q for more detailed information, which we intend to file shortly.”
“In addition to the financial details included in today's call, we encourage you to refer to Zevra's annual report on Form 10-K for more detailed information, which we intend to file within the next few days.”
“While I will provide a detailed financial overview during today's call, I encourage you to review Zevra's quarterly report on Form 10-Q for more detailed information, which we intend to file post-market tomorrow, November 13, 2024.”
Affiliation history
-
Start not stated–2025-12-31
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Zevra Therapeutics, Inc. (ZVRA) | MBA, CPA Former Chief Financial Officer and Treasurer | $477,307 | $3,821,924 |
| 2024 | Zevra Therapeutics, Inc. (ZVRA) | MBA, CPA Former Chief Financial Officer and Treasurer | $460,867 | $1,450,273 |
| 2023 | Zevra Therapeutics, Inc. (ZVRA) | MBA, CPA Chief Financial Officer, Secretary and Treasurer | $446,480 | $2,263,257 |
| 2022 | Zevra Therapeutics, Inc. (ZVRA) | MBA, CPA Chief Financial Officer, Secretary and Treasurer | $410,975 | $1,038,007 |
| 2021 | Zevra Therapeutics, Inc. (ZVRA) | Chief financial officer, secretary and treasurer | $370,993 | $1,056,212 |
| 2020 | Zevra Therapeutics, Inc. (ZVRA) | Chief financial officer, secretary and treasurer | $350,200 | $541,114 |
| 2019 | Zevra Therapeutics, Inc. (ZVRA) | Chief financial officer, secretary and treasurer | $348,500 | $664,487 |
| 2018 | Zevra Therapeutics, Inc. (ZVRA) | Chief financial officer, secretary and treasurer | $337,500 | $647,324 |